Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YESSSSSSSSSSSSSSSSSS - May 2024 Letter to Shareholders: "Following lifting of the clinical hold, we have observed a significant increase in third parties that are interested in partnering with the Company."
Now I am really liking Japan more and more. They just told the WHO to take a hike!!
To take their proposed future pandemic treaty and shove it was music to sovereign ears.
Yep, we need to get to Japan for some trials. The Japs do things right.
Dr. Jay is doing a superb job. The pigeons who faulted all of the company just
because of our ex CEO are out of step with reality. I don't get it. They cannot admit and support
the new CEO who is one of the worlds authority on HIV and leronlimab. He has done a fabulous job
thus far and must be admitted by all who understand what it took to satisfy the FDA with all their changing criteria for removing the holds. What a struggle. Now as we see from the PR just released exactly where we are going and what to expect. That PR was one of the best updates from a pharmaceutical company that
I can recall. Only one other was on par with it in my experience of researching Pharma and that is an Australian Pharma. Yet, short pigeons working for Pig Pharma are ecstatic that the PPS was violently shorted. It shows the resistance to leronlimab for the huge threat that it imposes. If a real threat did not exist, there would be no pigeons.
So now we are moving up in the breakout boards here and there. The time is coming without a doubt that a combo or cooperative agreement is in the works. 2024 will be the year of upward pps movement as the company finally finds it's legs.
Are you bullsh yet? Should be, because huge short funds have taken up all the stock... just cannot get any to borrow.
The time is getting ripe for a really strong squeeze. It will be one to remember. $$$CYDY$$$ 2024
Everybody should put their shares up for sale at the highest price allowed by your brokerage. This does not have the effect that it once had.....
but but but, it adds extraordinary pressure for brokerages to limit the exposure. I would dare say that there is an inordinate amount of illegal
shorting going on as well. The power of that down pressure Friday only exists because of the powerful strength of leronlimab. Too bad the SEC
doesn't push for transparency. The shorts would be exposed and no doubt one would find the chat sites abandoned by them abruptly.
Wow. What a nasty person you are Djjazz. Using words like idiot and moron. Why such language ?
You seem angry. And if someone wants to sell at $3, how is that ‘suddenly’ turning green and bailing out. A $3 price from here is a 1500% gain. How is that ‘bailing out’?
Mountainman5 glad you are back.
Had a little left in my trading account and bought a few more CYDY shares late Friday.
Every little bit helps.
Have problems with my account with Charles Schwab. I looked up in history section and discovered that a few of my CYDY shares disappeared, no, I would say quite a few disappeared,
They used the word "journal", after the ticker symbol within the row of other symbols and behind the word journal is nothing but an empty space, where it used to say, bought {"or sell"} the price and the number of shares. They left the date also.
I accumulated CYDY , starting many years ago, little by little with spare money.
Nowadays I wondered why my account was short of shares.
Is it possible, that the FDA have their long stretched arms out to every major trading company??
i'm not the one who spends all day (every day) on an obscure OTC chat board......
[quoteThe real question is whether or not we'll see a reputable partner step in, per Jay's comments. That would be the big][/quote]
Agreed, you have to see something substantial like that to see a continued share price increase beyond riding the current small cap stock upward trend-- that only takes you so far.
But, the liquidity issue has peeked my interest, this is by best month since 2021, so I will research it a little when I have time this week. Covid played a big role, but also the bull market spread out from large caps to small caps, and the small cap bull hit 2021. Small caps haven't done as well since then compared to large caps, interest rates a factor many think. We could be seeing a similar bull spread out to small caps now. But numbers are needed. I just checked and and last month OTC did $45B in dollar volume, up 50% from the $30B April 2023, link below. Not surprising I made 50% more last month than April 2023 trading, liquidity = money in my case. That number is climbing, but I don't have the 2021 numbers to compare. It would be interesting to see a 2021-2024 monthly $ volume chart for all OTC. Then we can visually see what is happening, and how that trend is progressing, and maybe help people make a little money for those paying attention to the trend if indeed we are at the start of a small cap bull run or middle etc.
https://otce.finra.org/otce/marketStatistics
I don't think we'll see anything close to 2021 in terms of that level of mania - simply because liquidity broadly has dropped by 90% since then, based on personal savings rate data - as the COVID stimulus money is pretty much exhausted. also, with rates up so much, credit is significantly tighter. That said, the GME, AMC and FFIE spikes were pretty incredible - and i don't understand it. Don't get me wrong, i'd love to see this run like it did in 2021 - if this thing spiked to $3 or $5, I'd unload my position pretty quickly :). But, i think it's highly unlikely in the near or intermediate term.
The real question is whether or not we'll see a reputable partner step in, per Jay's comments. That would be the biggest thing in the history of this company - as it would finally validate our drug, with an experienced player committing to Leronlimab.
Don't know why he would mention it if something wasn't close. I guess we'll see.
NEXT WEEK $ 0,30!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Greetings, from, yes, a proponent for (based on the information) Leronlimab.
Now "information" could be total "garbage" but saving the life of the former President of the Philippines, was Out-of-OUR-Hands! and along with other accounts, has kept me here.
And if this >> Lerolimab >> does moderate the CCR5 "pathway," moderate inflammatory processes, as well as cross the Blood-brain barrier
with MINIMAL NEGATIVE EFFECTS/REACTIONS
Wow!
........even YOU have to have some ambivalence.
Because your "clock is ticking" like mine and there's the potential to "enhance" the number of >>TICKS!
bRAVO - LERONLIMAB !!
Now this is based on what I've read/heard/discovered BUT YOU must perform your OWN "due diligence!"
So consider ALL, IMO!
***
WOWWWW - I AM VERY BULLISH FOR CYDY!!!!!!!!!!!! BIG SUPPORT AND THANKS TO OUR CEO!!!!!!!!!!
At $.50 yet! Thanks for the comedy! Make next pump. Now wait for Monday
These idiot longs have been through the pump and dump pattern dozens of times and they still can't see it. Gonna be funny when they all run away as it crashes. Hodl hodl! Right losers? LAUGHING
I’m not paying attention to this drivel but promise to come back next week when it’s back to $.15!
I’ll be here to remind you! Enjoy the pump and the weekend
I thought it was a very good letter, and I'll take it.
The very specific mention of partners and reference to near term was interesting - why would Jay make that specific comment if it wasn't true - because we'll know one way or the other soon enough. If there was nothing there he would be silent.
To be clear, I've been burned too many times in the past waiting for big news, but the tone he took suggests he fully believes this is a viable go-forward company - and at this point, i had been wondering about that. I have no idea if this move is for real, but i'm thankful for the communication, and hoping we see some further momentum.
Um, mountainman, how many times has this stock made one look like a fool after all the ALL CAPS!!!! yodeling on this board over the years?
And forget about conducting another prayer vigil over on reddit...begging for mercy will not help leronsaline or this stock.
LAUGHING
10.000 BITCOINS WOULD BE GREAT NOW!!!!!!!!!!!! LERONLIMAB IS ALSO GREAT AND UNIQUE!!!!!!!!!!!! ABSOLUTELY NO INFLATION!!!!!!!!!!!
Hey, did u notice we are not going to .10Centavos? LMAO
Up 30% already, oh now 34%!! .. ouch. Did u pull up those shorts yet??? LMAO (oh yes, "i am not short, but if I was")
Almost double from the bottom... oh yes, thanks for the cheapies. LMAO
Go Mr. M & A. You da man. Grip it and sip it all day and all weekend.
I love my weekends. Have a good one. LMAO
$$CYDY$$ 2024
ps. can u shorts see the catalyst yet? Can u see all the work that has been going on. What did u think was happening???
Where has u'r BS gotten you now? LMAO .50 cents coming soon with the additional updates hinted at. Look for it soooooonnn!!! LMAO...at fools.
BITCOIN AND CYDY ARE VERY BULLISH TODAY!!!!!!!!!!!!!!!!!!!
WE WILL SEE SOON VERY LARGE VOlUME!!!!!!!!!!!!
You might be correct. Volume in OTC comes and goes in cycles, the 01 was the biggest spike from all the Covid money and people with free time. This is my biggest week since 01 trading. Hopefully this wave is just started and continues for some time, as people make money, they roll it over in other stock in the FOMO mania going on right now.
I hope this goes to $.30 today! Jay Jay cashes in the $400k he’s owed on the shares he was given, warrant holders exit and the inevitable crash back to $.14 next week.
Like clockwork
YESSSSSSSSSSSS - GOOOOO CYDY GOOOOO AMERICA!!!!!!!!!‘n
Tons of COVID cash floating around in 2021, especially in the pockets of the younger generation who use social media for trading. Those same traders don’t have that cash. Fake head pump going on.
Why must you embarrass yourself on the daily! The reason Nader, Kelly, Cyrus and Jay love dupes like you is that you don’t know how to read text or discern bullshit…. You seek what you covet to help ease the burden of owning this shit stock’
Now look at my “bet” challenge and contrast it to what you claim the bet was. Do you and others get tired being wrong and conned?
My bet verbatim:
Noted that you don’t have the stones to take the bet
I thank you for your totally worthless opinion about the CytoDyn shareholder letter. If there was nothing to write about, I'm sure as we have seen in the past, nothing would have been written.
You know Grip and Sip yesterday invited me to a wager - his sticky post says that the CYDY share price will be ten cents by this July 2024. I disagreed, which prompted him to wager a bet - that if the price is indeed ten cents that I remove myself from this board, and if it is above that price, he will remove himself from this board.
I think it would be lovely if you and he removed yourselves from this board by July 1, 2024, if the share price is above 11 cents.
After the AMC and GME run this week that Zach Morris started two weeks ago, that Roaring Kitty ignited by liking his post, after his discord group loaded . They are running small cap tickers, anything under 10c ran, like FFIE 4c to $2. Or CRKN or KXIN or AKAN or GWAV running right now, etc. if this plays out like 2021, they will start running OTC tickers next, trips, then pennies, etc. I remember back in 2021, there wasn’t a single nasdaq small cap under $1, because they ran them all. No trip OTC, etc. Anyway, to be short any ticker right now before we see how this plays out is dangerous imo.
Just saying…
Real companies announce when they have partnerships. They don't go err ern we are talking em um with several err umm for literally YEARS. They have been saying this FOR YEARS you buffoons!!!
CYDY longs are complete morons.
How many times you going to fall for the same thing?
I summon Janice Shell: to hear from you about today's concise (not a "Grip It" summation) letter from CytoDyn.
I think it was good of him to write it. But it doesn't contain any real news, or much reason to hope to hear some in the foreseeable future.
Yada yada. This is Grip’s best shuffleboard game.
Shorting this garbage is stealing money! Watch and learn!
Yes Grip, these guys need to manufacture some fresh pump material instead of the same tired redundant nonsense.
It amazes me how a co can "potentially" this and "we expect" that without cash in hand to "prospectively" do this or that.
Yep, a cynic might think its all one grandiose circle jerk to dump shares on clueless rubes.
One would almost think that puff piece wasn’t sent out ten other times over the years. A cynic might think this great copy and paste letter was used to juice the price for a day or so to let warrant holders out.
But considering this company has always delivered on promises, I find this shareholder letter highly encouraging!
Bahahahaj! Just kidding! If I shorted stocks, which I don’t, I would short the shit out of this and cash out Tuesday for an easy 20%
Yes lets review the pumper talk bolded in red---
Over the next six months, we expect to commence at least one, and potentially two clinical trials. The prospective clinical trials, in order of priority, are: (i) a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer; and (ii) a Phase II study exploring leronlimab’s effects on inflammation. The Company’s priority will be the oncology trial which, if successful, will put us on track towards a commercial approval of leronlimab in that indication.
This sentence: "The Company’s priority will be the oncology trial which, if successful, will put us on track towards a commercial approval of leronlimab in that indication."
(sigh) Dupes will never learn....
Mountainman is alive!!
Yes yes!!
Much better with shareholder letter communication!!
anticipate finalizing agreements with these partners in the very near future !!
significant increase in third parties that are interested in partnering with the Company !!
the potential for significant value return at little or no cost to the Company !!
Wowzers !!
10.000 BITCOINS WOULD BE A NICE CAPITAL INJECTION FOR CYDY
I TRUST OUR CEO DR. JACOB LALEZARI 100 %!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
WITHOUT HEALTH THERE IS NO HAPPINESS!!!!!!!!!!!!!!!!!!!! GOD BLESS CYTODYN GOD BLESS AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!
You have any idea how many times this company has said "we expect" only for it never to materialize you complete buffoon? A lot.
LERONLIMAB = CYDY = AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!
LERONLIMAB IS A GAME CHANGER MEDICINE AND UNIQUE AND I STILL STRONG BELIEVE THAT CYDY WILL BE A BP IN FUTURE!!!!!!!!!!!!!!!!!!!!!!
CEO DR. JACOB LALEZARI: "........... IN THE VERY NEAR FUTURE!!!!!!!!!!!!!!!"
GREAT LETTER AND TRUST-BUILDING COMMUNICATION FROM OUR CEO DR. JACOB LALEZARI!!!!!!!!!!!!!!!!!!!!! BIGGGGGGGGGG SUPPORT AND RESPECT AFTER ALL WHAT HAPPENED!!!!!!!!!!!!!!!!!!!!!!!!!!!
GOOOOOOOOOOOOOOOOO CYDY GOOOOOOOOOOOOOOO AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!!
Bahahahaha!
The same dolt that said it would never be below $1.00 a couple years ago is excited about $.18
Look at my other post and come back Monday to admit how silly your post was. You’ll never learn
This letter is version #325 of the same nonsense! All “plan to”, “hope to” etc! This serves two purposes:
1) spin the baggies into a lather over $.18 stock
2) warrant and gifted shares are being unloaded on the pump! Educate yourself and look at the price JayJay needs to sell at! Then follow the Form S-4 down the road!
Schools out! You’ve been warned. Come Monday, $.13-.14 and reality hits. Enjoy the day of green before the implosion
Followers
|
810
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
232425
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |